Mature results of a phase II study of rituximab therapy for nodular lymphocyte-predominant Hodgkin lymphoma.

J Clin Oncol

Ranjana H. Advani, Sandra J. Horning, Richard T. Hoppe, Sarah Daadi, John Allen, and Yasodha Natkunam, Stanford University Medical Center, Stanford, CA; and Nancy L. Bartlett, Washington University School of Medicine, St Louis, MO.

Published: March 2014

Purpose: Universal expression of CD20 by malignant cells in nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) led us to evaluate rituximab (R) as a therapeutic option.

Patient And Methods: Patients with previously treated or newly diagnosed NLPHL were treated with R (375 mg/m(2) once per week for 4 weeks) or, after a protocol amendment, with R plus R maintenance (MR; administered once every 6 months for 2 years). Primary and secondary outcome measures were progression-free survival (PFS) and overall response rate (ORR), respectively.

Results: A total of 39 patients were enrolled (R, n = 23; R + MR, n = 16). After four once-per-week treatments, ORR was 100% (complete response, 67%; partial response, 33%). At median follow-ups of 9.8 years for R and 5 years for R + MR, median PFS were 3 and 5.6 years (P = .26), respectively; median overall survival (OS) was not reached. Estimated 5-year PFS and OS for patients treated with R versus R + MR were 39.1% (95% CI, 23.5 to 65.1) and 95.7% (95% CI, 87.7 to 100) versus 58.9% (95% CI, 38.0 to 91.2) and 85.7% (95% CI, 69.2 to 100), respectively. Nine of 23 patients experiencing relapse had evidence of transformation to aggressive B-cell lymphoma; six of these patients had infradiaphragmatic involvement at study entry.

Conclusion: R is an active agent in NLPHL. Although responses are not durable in most patients, a significant minority experience remissions lasting > 5 years. R + MR results in a nonsignificant increase in PFS compared with R. R may be considered in the relapsed setting for NLPHL. The potential for transformation of NLPHL to aggressive B-cell lymphoma underscores the importance of rebiopsy and long-term follow-up.

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2013.53.2069DOI Listing

Publication Analysis

Top Keywords

nodular lymphocyte-predominant
8
lymphocyte-predominant hodgkin
8
hodgkin lymphoma
8
patients treated
8
years median
8
aggressive b-cell
8
b-cell lymphoma
8
patients
6
nlphl
5
years
5

Similar Publications

Background: T/histiocyte-rich large B-cell lymphoma (T/HRBCL) is a highly aggressive subtype of diffuse large B-cell lymphoma characterized histologically by the presence of a few neoplastic large B cells amidst an abundant background of reactive T lymphocytes and/or histiocytes. T/HRBCL commonly affects the lymph nodes, followed by extranodal sites, such as the spleen, liver, and bone marrow, with rare occurrences in the gastrointestinal tract. Primary gastrointestinal T/HRBCL lacks specific clinical and endoscopic manifestations, and it is difficult to differentiate from inflammatory diseases, nodular lymphocyte predominant Hodgkin lymphoma, and other diseases on a histological basis, thereby hindering early diagnosis.

View Article and Find Full Text PDF

CD4CD8 double-positive T cells in immune disorders and cancer: Prospects and hurdles in immunotherapy.

Autoimmun Rev

January 2025

Department of Toxicology and Cancer Biology, Collage of Medicine, University of Kentucky, Lexington, KY 40536, USA; Markey Cancer Center, University of Kentucky, Lexington, KY 40536, USA. Electronic address:

CD4 and CD8 T cells play critical roles in both innate and adaptive immune responses, managing and modulating cellular immunity during immune diseases and cancer. Their well-established functions have led to significant clinical benefits. CD4CD8 double-positive (DP) T cells, a subset of the T cell population, have been identified in the blood and peripheral lymphoid tissues across various species.

View Article and Find Full Text PDF

Nodular lymphocyte-predominant Hodgkin lymphoma revisited: current management strategies and future perspectives.

Leuk Lymphoma

January 2025

First Department of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Dusseldorf, University of Cologne, Cologne, Germany.

Article Synopsis
  • Nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) is a rare type of lymphoma, making up about 5% of Hodgkin lymphoma cases, and shares some characteristics with B-cell non-Hodgkin lymphoma.
  • NLPHL is typically diagnosed at early stages and has a slow progression, leading to excellent long-term survival rates for most patients.
  • Treatment mainly mirrors classical Hodgkin lymphoma but may include rituximab; future strategies could involve innovative therapies like CAR T-cell therapy and bispecific antibodies.
View Article and Find Full Text PDF

Background: In children, nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) is an uncommon subtype of Hodgkin lymphoma. Given the lack of data on the best chemotherapy regimen, there is a knowledge gap in best management.

Methods: This retrospective study included all pediatric patients with NLPHL diagnosed and treated at the Children's Cancer Hospital, Egypt (2007-2018).

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!